A Phase 2 interventional study of Rapamune (sirolimus/rapamycin) in Ataxia-Telangiectasia (A-T) and Ataxia-Telangiectasia, sponsored by Sara Elva Espinosa Padilla, MD. Completed at 1 site in Mexico. Open to participants aged Up to 16 Years. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Sara Elva Espinosa Padilla, MD · Phase 2, Interventional, and Treatment
Ataxia-telangiectasia (A-T) is a progressive disease which is, to date, incurable, affecting motor skills, and a high cancer and recurrent infections risk. Although there has been great progress in recent years in understanding its pathophysiology, we have little information that produces any benefit for its treatment. Thus, Sirolimus has a wide variety of potential mechanisms of action that could be beneficial in A-T, including neuroprotective effects, antiangiogenic, anti-infectious, antineoplastic, and aging slower. With that aim, we conducted a pilot study in our hospital evaluating the safety and potential benefit of sirolimus in the disease.
42 studies on the registry are indexed under Ataxia Telangiectasia; 7 are open to participants now.
This study's enrollment of 6 is below the median of 30 across 28 interventional studies indexed under Ataxia Telangiectasia.
Browse Ataxia Telangiectasia studies →This is the only study on the registry with Sara Elva Espinosa Padilla, MD as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After baseline evaluation, oral sirolimus was initiated at a dose of 1 mg/m²/day divided into two daily doses. Treatment duration was 6 months, safety was assessed throughout the trial. Laboratory studies and adverse events were assessed every 2 months.
Drug: Rapamune (sirolimus/rapamycin)
Drug page: Sirolimus
After baseline evaluation, oral sirolimus was initiated at a dose of 1 mg/m²/day divided into two daily doses. Treatment duration was 6 months, safety was assessed throughout the trial.
Also known as: Sirolimus
Adverse effects and laboratory safety after treatment
After baseline evaluation, oral sirolimus was initiated at a dose of 1 mg/m²/day divided into two daily doses. Treatment duration was 6 months, safety was assessed throughout the trial. Laboratory studies and adverse events were assessed every 2 months.
Time frame: From enrollment to the end of treatment at 6 months
Neurological function assessed by the Scale for the Assessment and Rating of Ataxia
Neurological function was assessed using the Scale for the Assessment and Rating of Ataxia (SARA). Total scores range from 0 to 40 points, with higher scores indicating greater severity of ataxia. Scores were assessed at baseline and after 6 months of sirolimus treatment.
Time frame: From enrollment to the end of treatment at 6 months
Immunological and laboratory evaluation
Baseline and follow-up immunological assessments were performed every 2 months and included serum immunoglobulin levels and lymphocyte subpopulation analysis. Lymphocyte proliferation was assessed using CFSE labeling (C34554; molecular probes). In brief, peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque density gradient centrifugation and labeled with carboxifluorescein succinimidyl ester (CFSE). Cells were then stimulated with anti-CD3 (clone OKT3) plus anti CD28 (clone CD28.2) monoclonal antibodies (1µg/ml each). In parallel, PBMCs were stimulated with phytohemagglutinin (PHA) plus interleukin 2 (IL-2). Lymphocyte proliferation was quantified by flow cytometric analysis of CFSE dilution. Expression of the ATM protein was assessed in peripheral blood mononuclear cells by Western blot analysis.
Time frame: From enrollment to the end of treatment at 6 months
Percentage of conjunctival vascular area
Conjunctival telangiectasia was assessed using standardized digital photographs. It was quantified as the percentage of segmented vascular area relative to the total conjunctival region of interest. Measurements were obtained at baseline and after 6 months of sirolimus treatment.
Time frame: From enrollment to the end of treatment at 6 months
Image Analysis
Conjunctival photographs were analyzed using Fiji (ImageJ version 2.16.0/1.54p). The conjunctival region of interest (ROI) was manually delineated, excluding eyelids, eyelashes, and surrounding background, and the total ROI area was measured in pixels. Color segmentation was performed using the Color Threshold function in the HSB color space with fixed parameters: Hue, 0-25; Saturation, 110-255; and Brightness, 90-255. Images were converted into binary masks, and the segmented vascular area within the ROI was measured in pixels. Conjunctival telangiectasia was expressed as the percentage of segmented vascular area relative to the total conjunctival ROI area. All images were analyzed by the same investigator using an identical workflow and fixed thresholding parameters.
Time frame: From enrollment to the end of treatment at 6 months
Cognitive performance assessed by the Cerebellar Cognitive Affective Syndrome Scale
Cognitive performance was assessed using the Cerebellar Cognitive Affective Syndrome Scale (CCAS). The total raw score ranges from 0 to 120 points, with higher scores indicating better cognitive performance. Assessments were performed at baseline and after 6 months of sirolimus treatment.
Time frame: From enrollment to the end of treatment at 6 months
Executive functioning assessed by the Behavior Rating Inventory of Executive Function, Second Edition
Everyday executive functioning was assessed using the Behavior Rating Inventory of Executive Function, Second Edition (BRIEF-2). The Global Executive Composite was analyzed using T-scores, with higher scores indicating greater executive dysfunction. Assessments were performed at baseline and after 6 months of sirolimus treatment.
Time frame: From enrollment to the end of treatment at 6 months
Emotional and behavioral functioning assessed by the Child Behavior Checklist
Emotional and behavioral functioning was assessed using the Child Behavior Checklist (CBCL). The Total Problems score was analyzed using T-scores, with higher scores indicating greater emotional and behavioral problems. Assessments were performed at baseline and after 6 months of sirolimus treatment.
Time frame: From enrollment to the end of treatment at 6 months
Ran from Jul 2024 to primary completion in May 2026, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus